Two Novel HBV Candidates Planned to Enter Clinical Development in 2018 GalNAc Conjugated RNAi Agent Nominated to Enter IND-Enabling Studies Strategic Partnership with Roivant to Launch Genevant, an RNA Therapeutics Company Company to Host a Corporate Update Conference Call Today at 4:30 PM ET

VANCOUVER, British Columbia and WARMINSTER, Pa. , April 30, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Thursday, May 3, 2018 at 1:30 PM

Capsid inhibitor with HBV RNA Destabilizer Demonstrate Complementary Efficacy Results Subcutaneous RNAi Agent Demonstrates Durable HBsAg Reduction Following a Single Dose VANCOUVER, British Columbia and WARMINSTER, Pa. , April 12, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation

Genevant aims to advance 5-10 product candidates into the clinic by 2020 across RNAi, mRNA, and gene editing modalities using Arbutus’ LNP and ligand conjugate platforms Genevant will be led by Executive Chairman Paris Panayiotopoulos , former CEO of ARIAD Pharmaceuticals through its 2017

VANCOUVER, British Columbia and WARMINSTER, Pa. , March 28, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced presentation of data at the 53rd Annual International Liver Congress of the

ARB-1467 Phase II Combination Study Beginning in 1Q18 Two New Drug Candidates Planned to Enter Clinical Development in 2H18 Over $200M in Cash Available to Fund Development of HBV Assets Company to Host a Corporate Update Conference Call Today at 4:30 PM ET VANCOUVER, British Columbia and...

VANCOUVER, British Columbia and WARMINSTER, Pa. , March 12, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will hold a conference call on Wednesday, March 14, 2018 at 1:30 PM...

Acuitas has No Further Rights to Use or Sublicense Arbutus LNP Technology Arbutus Consolidates LNP Patent Estate Enabling RNAi, mRNA, and Gene-editing Therapeutics VANCOUVER, B.C. and WARMINSTER, Pa. , Feb. 22, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an...

VANCOUVER, British Columbia and WARMINSTER, Pa. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that Arbutus and Roivant entered into an exclusivity agreement (Exclusivity...

VANCOUVER, British Columbia and WARMINSTER, Pa. , Feb. 13, 2018 (GLOBE NEWSWIRE) --   Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced today that Bruce Cousins , Executive Vice President and Chief Financial Officer, is...